Eli Lilly (LLY)

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.

The stock continues to look unstoppable.

It's yet another setback for the drugmaker.

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

It has proven to be a market-beater in more years than not.

Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.

Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow...

Novo Nordisk is playing catch-up in the GLP-1 race.

Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from El

SpaceX has attractive prospects, but the market has already factored that into its share price.

Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

One of its more popular products just got the green light from a major national regulator.

During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start.

It's not much of a rivalry yet.

XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.

Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?

Berobenatide is one of the keys to Pfizer's future.